Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab neutrophil function in RA
NCT01195272Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2010
- Primary completion
- Mar 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Mean Percentage of Cells Staining Positive for Annexin V Binding in Apoptosis at Week 24, Mean Percentage of Cells Staining Positive for Annexin V Binding With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) at Week 24 and 10 more. Started Aug 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01195272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195272.